Roivant Sciences (NASDAQ:ROIV) Stock Update and Phase 3 VALOR Study Results

• Citigroup adjusted its rating for Roivant Sciences (NASDAQ:ROIV) to Neutral, while Bank of America raised its price target to $16.50.
• Roivant announced positive results from its Phase 3 VALOR study, showing significant improvements in treating dermatomyositis with brepocitinib.
• The company plans to file a New Drug Application (NDA) in the first half of 2026, with a current stock price of $14.99.

Roivant Sciences (NASDAQ:ROIV) is a biopharmaceutical company focused on developing transformative medicines. On September 18, 2025, Citigroup adjusted its rating for Roivant to Neutral, maintaining a hold action. At that time, the stock price was $15.47. Bank of America also raised its price target for Roivant from $12 to $16.50, as highlighted by TheFly.

Roivant recently announced positive results from its Phase 3 VALOR study, conducted with Priovant Therapeutics. The study evaluated brepocitinib for treating dermatomyositis (DM). The results showed that a 30 mg daily dose led to significant improvements compared to a placebo. This success was evident in both the primary endpoint and all nine key secondary endpoints.

The study's findings are promising, with brepocitinib achieving a week 52 mean Total Improvement Score (TIS) of 46.5, compared to 31.2 for the placebo group. The p-value of 0.0006 indicates strong statistical significance. More than two-thirds of patients on the 30 mg dose experienced at least a moderate response, and nearly half achieved a major response.

Roivant plans to file a New Drug Application (NDA) in the first half of 2026, following the consistent safety profile of brepocitinib. The company will also host an investor call to discuss these findings. Currently, ROIV's stock price is $14.99, reflecting a decrease of approximately 1.93% or $0.30. The stock has fluctuated between $14.98 and $15.52 today.

Over the past year, ROIV has reached a high of $16.05 and a low of $8.73. The company has a market capitalization of approximately $10.23 billion. Today's trading volume for ROIV is 2,323,718 shares, indicating active investor interest.